Eurofins Biomnis code

ADAL

Synonyms

• adalimumab
• Amgevita
• Amsparity
• anticorps anti-adalimumab
• Hukyndra
• Hulio
• Humira
• Hyrimoz
• Idacio
• Imraldi
• Libmyris
• Yuflyma

Specialty

Immunology

Clinical significance

Adalimumab is a humanised monoclonal antibody that binds specifically to TNFalpha, neutralising its biological function by blocking its interaction with TNFalpha receptors located on the cell surface. TNFalpha is produced by the body's cells and promotes inflammation, particularly in chronic inflammatory diseases such as chronic inflammatory bowel diseases (Crohn's disease, ulcerative colitis) or inflammatory rheumatic diseases (rheumatoid arthritis, ankylosing spondylitis). Anti-adalimumab antibodies may develop in response to treatment. They may have no clinical consequences or, conversely, may be responsible for a loss of clinical remission. Adalimumab and anti-adalimumab antibody levels should be measured in cases of loss of clinical response to biotherapies, drug optimisation, change of drug class, addition of an immunosuppressant, dose reduction or discontinuation of treatment.

Preanalytics

• 1 mL :
• Serum
•   Refrigerated

• A tube specifically for this analysis : No

Further information

[To be translated]
Please attach the specific clinical information sheet (R46 : Anti-TNF)

Documents to download

• Specific

Methodology

Chemiluminescence

Turnaround time

8 days